Companies / Poland
Tarchomin To Enter Polish Insulin Market
March 2006 | Company Finance AlertPolish drug maker Polfa Tarchomin is planing to capture 3% of the PLN500mn (US$156mn) Polish insulin market this year, despite the dominance of the multinationals Novo Nordisk and Eli Lilly and local leader
Sorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Emerging Europe Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Emerging Europe Pharma & Healthcare Insight please click on the trial link below.
